• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket

    2/24/23 7:56:26 AM ET
    $AKBA
    $AMAM
    $AMST
    $ATLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AKBA alert in real time by email

    Gainers

    • Cingulate Inc (NASDAQ:CING) rose 85.7% to $2.08 in pre-market trading after the company disclosed top-line results from Fed/Fast study of lead asset CTx-1301 for ADHD.
    • Akebia Therapeutics Inc (NASDAQ:AKBA) rose 17.5% to $0.87 in pre-market trading. Akebia received CHMP opinion in Europe for vafseo for treatment of symptomatic anaemia associated with chronic kidney disease in adults on chronic maintenance dialysis.
    • Lucira Health Inc (NASDAQ:LHDX) shares rose 17.1% to $0.14 in pre-market trading. Lucira Health shares dropped over 45% on Thursday after the company announced it will pursue a strategic sale of its business through the voluntary Chapter 11 process.
    • Atlas Lithium Corp (NASDAQ:ATLX) rose 15.5% to $22.95 in pre-market trading after gaining 60% on Thursday. Atlas Lithium, last month, signed a MOU with Mitsui & Co. with respect to Mitsui's potential interest in acquiring the right to purchase Atlas Lithium's future lithium concentrate production.
    • AIM ImmunoTech Inc (NYSE:AIM) shares rose 15.2% to $0.57 in pre-market trading. AIM ImmunoTech, last month, entered into a sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca.
    • Beyond Meat Inc (NASDAQ:BYND) rose 14% to $19.54 in pre-market trading after the company reported better-than-expected financial results for its fourth quarter on Thursday.
    • Amesite Inc (NASDAQ:AMST) rose 11.6% to $2.70 in pre-market trading. Amesite recently announced a 1-for-12 reverse stock split.
    • Troika Media Group Inc (NASDAQ:TRKA) rose 11.5% to $0.29 in pre-market trading. Troika Media Group retained Jefferies LLC to help explore strategic alternatives.
    • Farfetch Ltd (NYSE:FTCH) rose 8.9% to $5.39 in pre-market trading after the company reported better-than-expected Q4 results. The company also said that its CFO will step down by end of 2023.
    • Block Inc (NYSE:SQ) shares rose 7.8% to $80.00 in pre-market trading as the company posted upbeat sales results for its fourth quarter.

    Losers

    • Nektar Therapeutics (NASDAQ:NKTR) shares fell 39.2% to $1.80 in pre-market trading after the company reported Phase 2 topline data for rezpegaldesleukin in patients with systemic lupus erythematosus.
    • Ocean Biomedical Inc (NASDAQ:OCEA) fell 17.1% to $8.95 in pre-market trading. Ocean Biomedical shares jumped around 125% on Thursday after the company issued a press release celebrating the discovery of bispecific antibodies and immune checkpoint inibitors that kill glioblastoma cells and melanoma cells and block the metastasis of malignant melanoma cells to the lung by over 90%.
    • Bigcommerce Holdings Inc (NASDAQ:BIGC) shares dropped 16.6% to $9.45 in pre-market trading after the company reported downbeat Q4 sales and issued weak sales forecast.
    • ContextLogic Inc (NASDAQ:WISH) fell 12.5% to $0.62 in pre-market trading after the company reported worse-than-expected fourth-quarter sales results.
    • Hexo Corp (NASDAQ:HEXO) fell 7.8% to $1.52 in pre-market trading after declining 3% on Thursday.
    • Ambrx Biopharma Inc - ADR (NYSE:AMAM) fell 7.5% to $6.04 in pre-market after jumping 45% on Thursday. Ambrx Biopharma recently announced initial data from its ongoing Phase 1 APEX-01 trial of ARX517, Ambrx's proprietary anti-PSMA ADC, in prostate cancer patients.
    • RedHill Biopharma Ltd (NASDAQ:RDHL) fell 6.9% to $0.20 in pre-market trading.
    • Vascular Biogenics Ltd (NASDAQ:VBLT) fell 6.8% to $0.16 in pre-market trading. Vascular Biogenics shares jumped around 30% on Thursday after the company and Notable Labs announced a definitive merger agreement.
    • Opendoor Technologies Inc (NASDAQ:OPEN) shares fell 5% to $1.73 in pre-market trading after reporting Q4 results.
    • Expion360 Inc (NASDAQ:XPON) fell 4.1% to $3.77 in pre-market trading after surging 42% on Thursday.

    Now Read This: Wall Street's Most Accurate Analysts Say Hold These 3 Healthcare Stocks Delivering High-Dividend Yields

    Get the next $AKBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKBA
    $AMAM
    $AMST
    $ATLX

    CompanyDatePrice TargetRatingAnalyst
    Nektar Therapeutics
    $NKTR
    2/10/2026Mkt Perform → Outperform
    William Blair
    Nektar Therapeutics
    $NKTR
    11/26/2025$102.00Buy
    Citigroup
    Beyond Meat Inc.
    $BYND
    10/24/2025$2.00 → $1.50Underperform
    Mizuho
    Beyond Meat Inc.
    $BYND
    9/15/2025Hold → Sell
    Argus
    Beyond Meat Inc.
    $BYND
    8/20/2025Underweight
    Analyst
    Opendoor Technologies Inc
    $OPEN
    8/13/2025$1.00Mkt Perform → Underperform
    Keefe Bruyette
    Opendoor Technologies Inc
    $OPEN
    8/7/2025Neutral → Sell
    Citigroup
    Opendoor Technologies Inc
    $OPEN
    6/27/2025Mkt Perform
    Citizens JMP
    More analyst ratings

    $AKBA
    $AMAM
    $AMST
    $ATLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

    Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

    3/28/24 10:46:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    $AMAM
    $AMST
    $ATLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief R&D Officer Zalevsky Jonathan sold $13,140 worth of shares (180 units at $73.00), decreasing direct ownership by 0.84% to 21,174 units (SEC Form 4)

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    2/20/26 7:10:29 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Robin Howard W sold $30,879 worth of shares (423 units at $73.00), decreasing direct ownership by 0.56% to 75,489 units (SEC Form 4)

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    2/20/26 7:10:10 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Rabois Keith was granted 14,679 shares, increasing direct ownership by 2% to 630,088 units (SEC Form 4)

    4 - Opendoor Technologies Inc. (0001801169) (Issuer)

    2/19/26 5:58:19 PM ET
    $OPEN
    Real Estate
    Finance

    $AKBA
    $AMAM
    $AMST
    $ATLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

    OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced updated terms for its previously announced rights offering (the "Rights Offering"). Each subscription right now entitles holders to purchase one unit (the "Units"), each Unit consisting of one share of the Company's Series G Convertible Preferred Stock (the "Preferred Stock"), and 2,000 Class G Common Stock Purchase Warrants to purchase the Compa

    2/27/26 9:00:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar web

    2/26/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

    Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) and AKB-097 Phase 2 rare kidney disease basket trial planned to begin in 2H 2026 Akebia to Host Conference Call at 8:00 a.m. EST on February 26, 2026 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ake

    2/26/26 7:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    $AMAM
    $AMST
    $ATLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. bought $34,317 worth of shares (6,809 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:19 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Werth Peter J. bought $98,053 worth of shares (19,455 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    $AMAM
    $AMST
    $ATLX
    SEC Filings

    View All

    SEC Form 424B3 filed by AIM ImmunoTech Inc.

    424B3 - AIM ImmunoTech Inc. (0000946644) (Filer)

    2/27/26 8:30:11 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Akebia Therapeutics Inc.

    10-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

    2/26/26 7:35:08 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

    2/26/26 7:04:39 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    $AMAM
    $AMST
    $ATLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nektar Therapeutics upgraded by William Blair

    William Blair upgraded Nektar Therapeutics from Mkt Perform to Outperform

    2/10/26 11:48:14 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Nektar Therapeutics with a new price target

    Citigroup initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $102.00

    11/26/25 8:36:15 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho reiterated coverage on Beyond Meat with a new price target

    Mizuho reiterated coverage of Beyond Meat with a rating of Underperform and set a new price target of $1.50 from $2.00 previously

    10/24/25 11:41:31 AM ET
    $BYND
    Packaged Foods
    Consumer Staples

    $AKBA
    $AMAM
    $AMST
    $ATLX
    Financials

    Live finance-specific insights

    View All

    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar web

    2/26/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

    Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) and AKB-097 Phase 2 rare kidney disease basket trial planned to begin in 2H 2026 Akebia to Host Conference Call at 8:00 a.m. EST on February 26, 2026 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ake

    2/26/26 7:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q4 2025 Open House: Opendoor 2.0 Does What It Said It Would Do — Delivering Acquisition Growth, Faster Inventory Turns, and Stronger Cohorts

    SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Opendoor Technologies Inc. (NASDAQ:OPEN), a leading e-commerce platform for residential real estate transactions, today reported financial results for its fourth quarter and year ended December 31, 2025. "Last quarter, we outlined a four-step plan to transform Opendoor: reach breakeven Adjusted Net Income by the end of 2026 on a 12-month go-forward basis, drive positive unit economics while increasing transaction velocity, transition to direct-to-consumer relationships, and expand our product suite. This quarter demonstrates we are executing on that plan," said Kaz Nejatian, CEO of Opendoor. "These results reflect structural improvements in

    2/19/26 4:05:00 PM ET
    $OPEN
    Real Estate
    Finance

    $AKBA
    $AMAM
    $AMST
    $ATLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by AIM ImmunoTech Inc.

    SC 13G - AIM ImmunoTech Inc. (0000946644) (Subject)

    11/14/24 3:21:36 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKBA
    $AMAM
    $AMST
    $ATLX
    Leadership Updates

    Live Leadership Updates

    View All

    Opendoor Names President and CFO to Accelerate Next Chapter

    MIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Opendoor Technologies Inc. (NASDAQ:OPEN) today announced two executive appointments designed to accelerate the Company's next phase of growth: President from the fintech frontier, and CFO promoted from within after an extensive external search. Accelerating our next chapter Lucas Matheson joins as President on December 22, 2025. Matheson most recently served as CEO of Coinbase Canada and previously spent five years at Shopify leading acceleration finance (M&A), strategic expansion, corporate financial planning & analysis and various operational roles. At Opendoor, Matheson will oversee Corporate Development, Financial Planning & Analysis, and em

    12/15/25 7:00:00 AM ET
    $OPEN
    Real Estate
    Finance

    Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights. Recent Highlights (Post-Q3) FDA Accepts NDA for CTx-1301; PDUFA Date Set for May 31, 2026In October of 2025, the U.S. Food and Drug Administration (FDA) accepted Cingulate's New Drug Application

    11/13/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

    Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate's transition toward commercialization pending FDA approval Company also strengthens its cash position by completing a $6 million financing KANSAS CITY, Kan., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced the appointment of Bryan Downey as Chief Commercial Officer, following the U.S. Food and Drug Administration's (FDA) acceptance of Cingulate's New Drug Application (ND

    11/10/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care